Hemispherx Biopharma has announced that an order of newly manufactured rintatolimod (Ampligen) for sale utilising the Early Access Programme (EAP) in Europe has been shipped with receipt confirmed on January 26.
In May 2016, the company executed an amended and restated agreement with Impatients NV, a Netherlands-based company operating as myTomorrows, for the commencement and management of an Early Access Programme (EAP) in all of Europe and Turkey. Ampligen is the trade name in the United States for rintatolimod.
“This new lot of rintatolimod (Ampligen) will enable Chronic Fatigue Syndrome (CFS) and Pancreatic Cancer patients in the EU and Turkey to access rintatolimod under early access regulations,” said Tom Equels, CEO of Hemispherx.
“The shipment of new product that has been recently released for use in the initiated EAP is an important tangible step in our effort to make our experimental drug Ampligen available to individuals with CFS and pancreatic cancer.”
About Rintatolimod: Rintatolimod is a member of a new class of specifically configured ribonucleic acid (RNA) compounds targeted as potential treatment of diseases with immunologic defects and/or viral causation.